FDA Drug Shortage: Sterile Water Irrigant (Current)

Lead

The FDA has designated Sterile Water for Irrigation as a drug in current shortage as of its most recent update to the Drug Shortages Database. The shortage stems from discontinuation of manufacture by the producing entity. Wholesale drug distributors and 3PLs handling sterile injectable products should review their inventory allocation protocols and customer communication procedures for this product category.

Background

Under Section 506E of the Federal Food, Drug, and Cosmetic Act (FD&C Act), enacted through the FDA Safety and Innovation Act of 2012, the FDA maintains a public Drug Shortages Database tracking medically necessary drugs in shortage. Manufacturers are required to notify FDA at least six months in advance of a permanent discontinuation or interruption in manufacturing that is likely to lead to a meaningful disruption in supply. The agency classifies shortages as "current," "resolved," or "discontinued" based on manufacturer reporting and market supply assessments.

Sterile Water for Irrigation is a large-volume sterile irrigation solution used in surgical and wound care settings. It is classified as a sterile drug product under 21 CFR Part 200 and must be manufactured under current good manufacturing practice (cGMP) requirements established in 21 CFR Parts 210 and 211. Unlike Sterile Water for Injection (which is administered parenterally), Sterile Water for Irrigation is not intended for intravenous use, but its sterility requirements remain stringent given its application to exposed tissue during medical procedures.

Key Details

According to the FDA Drug Shortages Database entry, the shortage reason is listed as "Discontinuation of the manufacture of the drug." The database does not specify which manufacturer discontinued production or whether multiple products under different NDC codes are affected. The designation "current" indicates the shortage is ongoing as of the database's last update.

The FDA has not issued a formal shortage alert or revised guidance specific to this product. The entry appears in the standard Drug Shortages Database, which is updated as manufacturers submit discontinuation notices under 21 USC 356c. No therapeutic alternative recommendations or import allocation procedures have been published by FDA for this specific shortage.

Wholesale distributors holding existing inventory of Sterile Water for Irrigation products are not subject to specific FDA allocation requirements at this time. However, entities with state wholesale drug distributor licenses may be subject to state-level shortage reporting or allocation requirements depending on jurisdiction. For example, California Health and Safety Code Section 4164 requires wholesale distributors to report certain drug shortages to the California State Board of Pharmacy.

Impact Assessment

Wholesale drug distributors and 3PLs should assess their current inventory positions for Sterile Water for Irrigation products. Entities serving hospital systems, ambulatory surgical centers, or wound care clinics may experience increased order volume as downstream customers seek to secure supply ahead of broader market recognition of the shortage.

Distributors should verify whether their trading partners have business continuity plans for sterile irrigation product shortages. Under DSCSA transaction information requirements (21 USC 360eee-1(b)(1)(A)), any change in product sourcing or addition of new trading partners to fulfill shortage-driven demand must be accompanied by compliant transaction documentation, including transaction information (TI), transaction history (TH), and transaction statement (TS).

3PLs providing temperature-controlled storage for hospital or surgical customers should confirm that any alternative sterile irrigation products substituted by their customers maintain compatible storage requirements. Sterile Water for Irrigation is typically stored at controlled room temperature (20-25°C), but alternative formulations may have different specifications.

State boards of pharmacy in certain jurisdictions require wholesale distributors to notify the board when a distributor cannot fill an order for a drug in shortage due to insufficient supply. Distributors operating in multiple states should cross-reference state-specific shortage notification requirements against their customer base for this product category.

What ColdChainCheck Data Shows

As of the current database snapshot, ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA establishment registrations — the foundational requirement for entities handling sterile drug products. The average compliance score across the directory is 51/100, placing the majority of tracked entities in the "Fair" tier (919 entities). Only 63 entities hold NABP accreditation, representing approximately 5% of the directory.

For entities involved in sterile irrigation product distribution, FDA registration status is non-negotiable. The 41 entities in ColdChainCheck's directory without confirmed FDA registration should not be considered for sourcing sterile products, regardless of state licensure status. Under 21 USC 360(b), every entity engaged in the manufacture, repackaging, relabeling, or salvaging of drug products must register with FDA and list the drugs it handles.

The compliance score distribution indicates that fewer than 2% of tracked entities achieve "Excellent" tier (28 entities) — defined as entities with comprehensive license coverage, active accreditation, and no enforcement actions on record. QA managers evaluating alternative suppliers during a shortage should prioritize entities in the "Good" (281 entities) or "Excellent" tiers, particularly those with NABP accreditation and multi-state licensure.

Practical Guidance for Compliance Officers

• Verify FDA registration status: Use the ColdChainCheck directory to confirm that any new or backup supplier holds active FDA establishment registration. Filter by "FDA Registration: Active" to narrow the list to 1,234 compliant entities.
• Cross-reference state licenses: If your facility operates in a state with specific sterile product handling requirements (e.g., California's additional registration for sterile compounding facilities), confirm the distributor holds the appropriate state-level license. ColdChainCheck displays state-by-state license status for each entity.
• Check enforcement history: Entities with FDA warning letters or recalls related to sterile product handling pose elevated risk during shortage conditions. ColdChainCheck tracks 73 entities with recalls on record — review the enforcement details before onboarding a new supplier.
• Monitor NABP accreditation: While only 63 entities in the directory hold NABP accreditation, this subset represents distributors with third-party verification of compliance with NABP Model Rules. During a shortage, accredited entities may be better positioned to handle increased volume without compliance lapses.

ColdChainCheck tracks FDA drug shortage designations as part of its ongoing regulatory monitoring. For related guidance on wholesale distributor due diligence requirements, see the compliance guides section.

Disclaimer: This content is provided for informational purposes only and does not constitute legal or regulatory advice. Entities should verify all regulatory requirements with the FDA, state boards of pharmacy, and qualified legal counsel before making sourcing or operational decisions.

Update: FDA Sterile Water Injection Shortage: Distributor Impact

March 19, 2026

FDA Reports Critical Sterile Water Injection Shortage Impacting Pharmaceutical Distribution

The FDA has added multiple sterile water for injection (SWFI) products to its drug shortage list as of January 2025, creating supply chain complications for wholesale drug distributors and healthcare facilities that rely on these products for drug reconstitution. The shortage affects multiple manufacturers and presentations, including 10mL, 20mL, and 50mL vials used across hospital and specialty pharmacy settings.

Regulatory Context

Sterile water for injection falls under 21 CFR Part 610.12 as a biological product used in the manufacture and reconstitution of injectable pharmaceuticals. The FDA Drug Shortages Program, established under the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and strengthened by the Coronavirus Aid, Relief, and Economic Security (CARES) Act, requires manufacturers to notify the agency at least six months before a discontinuation or interruption in supply that could lead to a shortage.

The current shortage is tracked on the FDA's Drug Shortages Database, which wholesale distributors are required to monitor as part of their trading partner due diligence under the Drug Supply Chain Security Act (DSCSA). While SWFI itself is not a prescription drug requiring DSCSA serialization, its availability directly impacts the distribution of lyophilized and powder injectable drugs that require reconstitution before administration.

Key Details of the Shortage

As of January 2025, the FDA shortage list identifies supply constraints for sterile water for injection across multiple NDC numbers and manufacturers. Affected presentations include:

• Sterile Water for Injection, USP (10mL single-dose vials)
• Sterile Water for Injection, USP (20mL single-dose vials)
• Sterile Water for Injection, USP (50mL single-dose vials)

The FDA has classified this as an active shortage, indicating that current supply is insufficient to meet projected demand. The agency has not issued an import alert relaxation or temporary compounding guidance as of this writing, meaning standard cGMP and USP <797> requirements remain in effect for any entity preparing sterile products.

Manufacturing delays and increased demand from healthcare facilities are cited as primary causes. The FDA has not identified a specific resolution timeline, stating only that affected manufacturers are "working to increase production."

Impact on Pharmaceutical Distribution

Wholesale drug distributors face three operational challenges from this shortage:

Allocation and prioritization: Distributors holding existing SWFI inventory must implement allocation protocols that prioritize critical-care facilities and specialty pharmacies preparing time-sensitive injectable therapies. This requires real-time inventory visibility and documented allocation policies to demonstrate equitable distribution during an FDA-monitored shortage.

Reconstitution-dependent product distribution: Distributors carrying lyophilized antibiotics, chemotherapy agents, and biologics that require SWFI for reconstitution may see order fulfillment delays if customers cannot source the necessary diluent. This creates a secondary constraint on otherwise available pharmaceutical inventory.

Regulatory documentation: Distributors must document their response to the shortage, including communications with downstream customers about limited availability and any allocation decisions made. State pharmacy boards and the FDA can request this documentation during inspections or shortage-related inquiries.

The shortage does not change DSCSA compliance requirements for the prescription drugs that rely on SWFI for reconstitution, but it does complicate the operational logistics of specialty pharmacy and hospital distribution channels that wholesale distributors serve.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA establishment registration — a baseline requirement for any distributor handling products on the FDA drug shortage list. However, the average compliance score of 51/100 indicates that many distributors maintain only minimal verified compliance signals beyond basic registration.

The shortage affects distributors differently based on their customer mix. Entities serving specialty pharmacies and hospital systems — particularly those distributing oncology and critical-care injectables — face immediate operational pressure. ColdChainCheck's directory shows that 281 entities score in the "Good" range (60-79 points), indicating multiple verified state licenses and NABP accreditation. These distributors typically have documented quality systems capable of implementing allocation protocols during shortage conditions.

Only 63 entities in the directory hold NABP Accreditation for Wholesale Drug Distribution (formerly VAWD). NABP-accredited distributors are required to maintain documented procedures for handling allocation during drug shortages, including prioritization criteria and communication protocols with downstream customers. This accreditation becomes a differentiator when healthcare facilities evaluate trading partners during constrained supply periods.

Practical Steps for QA and Procurement Teams

• Verify your distributor's FDA registration status: Use the ColdChainCheck directory to confirm that your wholesale distributor holds current FDA establishment registration. Entities without active registration cannot legally distribute SWFI or the injectable products requiring it for reconstitution.

• Check for shortage-related enforcement signals: Review whether your trading partners have FDA warning letters or recalls on record. ColdChainCheck tracks 73 entities with enforcement actions — during shortage conditions, distributors with clean regulatory records are less likely to face supply interruptions from compliance issues.

• Document shortage communications: If your distributor implements allocation, request written documentation of their prioritization criteria. This documentation supports your own compliance file if audited on why certain injectable products were unavailable.

• Cross-reference state licensure: Verify that your distributor holds active licenses in the states where your facilities operate. The state-by-state directory filters show licensure coverage — critical if you need to source SWFI or related products from alternate distributors during the shortage.

ColdChainCheck monitors FDA drug shortage alerts and cross-references them against tracked entities. For broader guidance on distributor qualification during supply chain disruptions, see the DSCSA compliance guides.

Disclaimer: This article provides informational content based on publicly available FDA data and regulatory sources. It is not legal or compliance advice. Consult your legal counsel and quality assurance team for guidance specific to your operations.